Cytoplan Limited - Period Ending 2020-08-31

Cytoplan Limited - Period Ending 2020-08-31


Cytoplan Limited 01493205 false 2019-09-01 2020-08-31 2020-08-31 The principal activity of the company is supplying vitamin, mineral and enzyme preparations Digita Accounts Production Advanced 6.26.9041.0 Software true false false false false 01493205 2019-09-01 2020-08-31 01493205 2020-08-31 01493205 core:RetainedEarningsAccumulatedLosses 2020-08-31 01493205 core:RevaluationReserve 2020-08-31 01493205 core:ShareCapital 2020-08-31 01493205 core:SharePremium 2020-08-31 01493205 core:FinancialAssetsCostLessImpairment core:CurrentFinancialInstruments 2020-08-31 01493205 core:CurrentFinancialInstruments 2020-08-31 01493205 core:CurrentFinancialInstruments core:WithinOneYear 2020-08-31 01493205 core:Non-currentFinancialInstruments core:AfterOneYear 2020-08-31 01493205 core:OtherResidualIntangibleAssets 2020-08-31 01493205 core:LandBuildings 2020-08-31 01493205 core:PlantMachinery 2020-08-31 01493205 bus:SmallEntities 2019-09-01 2020-08-31 01493205 bus:Audited 2019-09-01 2020-08-31 01493205 bus:FullAccounts 2019-09-01 2020-08-31 01493205 bus:SmallCompaniesRegimeForAccounts 2019-09-01 2020-08-31 01493205 bus:RegisteredOffice 2019-09-01 2020-08-31 01493205 bus:CompanySecretaryDirector1 2019-09-01 2020-08-31 01493205 bus:PrivateLimitedCompanyLtd 2019-09-01 2020-08-31 01493205 core:RetainedEarningsAccumulatedLosses 2019-09-01 2020-08-31 01493205 core:RevaluationReserve 2019-09-01 2020-08-31 01493205 core:ShareCapitalOrdinaryShares 2019-09-01 2020-08-31 01493205 core:SharePremium 2019-09-01 2020-08-31 01493205 core:Non-standardIntangibleAssetClass1ComponentIntangibleAssetsOtherThanGoodwill 2019-09-01 2020-08-31 01493205 core:OtherResidualIntangibleAssets 2019-09-01 2020-08-31 01493205 core:LandBuildings 2019-09-01 2020-08-31 01493205 core:PlantMachinery 2019-09-01 2020-08-31 01493205 core:Subsidiary1 2019-09-01 2020-08-31 01493205 core:Subsidiary1 countries:AllCountries 2019-09-01 2020-08-31 01493205 core:Subsidiary2 2019-09-01 2020-08-31 01493205 core:Subsidiary2 countries:AllCountries 2019-09-01 2020-08-31 01493205 1 2019-09-01 2020-08-31 01493205 countries:England 2019-09-01 2020-08-31 01493205 2019-08-31 01493205 core:RetainedEarningsAccumulatedLosses 2019-08-31 01493205 core:RevaluationReserve 2019-08-31 01493205 core:ShareCapitalOrdinaryShares 2019-08-31 01493205 core:SharePremium 2019-08-31 01493205 core:OtherResidualIntangibleAssets 2019-08-31 01493205 core:CostValuation 2019-08-31 01493205 core:LandBuildings 2019-08-31 01493205 core:PlantMachinery 2019-08-31 01493205 2018-09-01 2019-08-31 01493205 2019-08-31 01493205 core:RetainedEarningsAccumulatedLosses 2019-08-31 01493205 core:RevaluationReserve 2019-08-31 01493205 core:ShareCapital 2019-08-31 01493205 core:ShareCapitalOrdinaryShares 2019-08-31 01493205 core:SharePremium 2019-08-31 01493205 core:CurrentFinancialInstruments 2019-08-31 01493205 core:CurrentFinancialInstruments core:WithinOneYear 2019-08-31 01493205 core:Non-currentFinancialInstruments core:AfterOneYear 2019-08-31 01493205 core:OtherResidualIntangibleAssets 2019-08-31 01493205 core:LandBuildings 2019-08-31 01493205 core:PlantMachinery 2019-08-31 01493205 core:RetainedEarningsAccumulatedLosses 2018-09-01 2019-08-31 01493205 core:RevaluationReserve 2018-09-01 2019-08-31 01493205 core:ShareCapitalOrdinaryShares 2018-09-01 2019-08-31 01493205 core:SharePremium 2018-09-01 2019-08-31 01493205 core:Subsidiary1 2018-09-01 2019-08-31 01493205 core:Subsidiary2 2018-09-01 2019-08-31 01493205 2018-08-31 01493205 core:RetainedEarningsAccumulatedLosses 2018-08-31 01493205 core:RevaluationReserve 2018-08-31 01493205 core:ShareCapitalOrdinaryShares 2018-08-31 01493205 core:SharePremium 2018-08-31 iso4217:GBP xbrli:pure

Company registration number: 01493205

Cytoplan Limited

Filleted Annual Report and Financial Statements

for the Year Ended 31 August 2020

 

Cytoplan Limited

Contents

Balance Sheet

1 to 2

Statement of Changes in Equity

3

Notes to the Financial Statements

4 to 13

 

Cytoplan Limited

(Registration number: 01493205)
Balance Sheet as at 31 August 2020

Note

2020
 £

2019
 £

Fixed assets

 

Intangible assets

4

221,195

92,805

Tangible assets

5

248,310

253,724

Investments

6

200

200

 

469,705

346,729

Current assets

 

Stocks

8

1,554,327

1,512,497

Debtors

9

210,399

371,130

Other financial assets

7

250,000

-

Cash at bank and in hand

 

2,001,222

1,264,508

 

4,015,948

3,148,135

Creditors: Amounts falling due within one year

10

(915,404)

(784,862)

Net current assets

 

3,100,544

2,363,273

Total assets less current liabilities

 

3,570,249

2,710,002

Creditors: Amounts falling due after more than one year

10

(14,200)

(15,250)

Provisions for liabilities

 

Provisions

 

(1,309,721)

(1,309,721)

Deferred tax liabilities

 

(73,036)

(58,951)

Provisions for liabilities

(1,382,757)

(1,368,672)

Net assets

 

2,173,292

1,326,080

Capital and reserves

 

Called up share capital

455,000

455,000

Share premium reserve

562,882

562,882

Revaluation reserve

9,647

9,647

Profit and loss reserve

1,145,763

298,551

Total equity

 

2,173,292

1,326,080

 

Cytoplan Limited

(Registration number: 01493205)
Balance Sheet as at 31 August 2020

These financial statements have been prepared and delivered in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006. The option not to file the profit and loss account and directors’ report has been taken.

Approved and authorised by the Board on 27 April 2021 and signed on its behalf by:
 


T D Higginson
Company secretary and director

   
 

Cytoplan Limited

Statement of Changes in Equity
for the Year Ended 31 August 2020

Ordinary share capital
£

Share premium
£

Revaluation reserve
£

Profit and loss reserve
£

Total
£

At 1 September 2019

455,000

562,882

9,647

298,551

1,326,080

Movement in year :

Profit for the year

-

-

-

1,097,212

1,097,212

Total comprehensive income

-

-

-

1,097,212

1,097,212

Gift aid payment

-

-

-

(250,000)

(250,000)

Total movement for the year

-

-

-

847,212

847,212

At 31 August 2020

455,000

562,882

9,647

1,145,763

2,173,292

Ordinary share capital
£

Share premium
£

Revaluation reserve
£

Profit and loss reserve
£

Total
£

At 1 September 2018

455,000

562,882

9,647

(195,098)

832,431

Movement in year :

Profit for the year

-

-

-

693,649

693,649

Total comprehensive income

-

-

-

693,649

693,649

Gift aid payment

-

-

-

(200,000)

(200,000)

Total movement for the year

-

-

-

493,649

493,649

At 31 August 2019

455,000

562,882

9,647

298,551

1,326,080

 

Cytoplan Limited

Notes to the Financial Statements
for the Year Ended 31 August 2020

1

General information

The company is a private company limited by share capital, incorporated in England.

The address of its registered office is:
Unit 8 Hanley Workshops
Hanley Road
Hanley Swan
Worcester
Worcs
WR8 0DX

2

Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

These financial statements are presented in Sterling (£).

Turnover recognition

Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenues earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risk and rewards of ownership of the goods have transferred to the buyer. Turnover from the rendering of services is recognised by reference to the state of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.

Government grants

Grants are accounted under the accruals model as permitted by FRS 102. Grants relating to expenditure on tangible fixed assets are credited to the profit and loss at the same rate as the depreciation on the assets to which the grant relates. The deferred element of grants is included in creditors as deferred income.

Grants of a revenue nature are recognised in the profit and loss in the same period as the related expenditure.

 

Cytoplan Limited

Notes to the Financial Statements
for the Year Ended 31 August 2020

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rate on the date when the fair value is re-measured.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in the profit and loss account, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Deferred tax is recognised on timing differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements and on unused tax losses or tax credits in the company. Deferred tax is determined using tax rates and laws that have been enacted or substantively enacted by the reporting date.

The carrying amount of deferred tax assets are reviewed at each reporting date and a valuation allowance is set up against deferred tax assets so that the net carrying amount equals the highest amount that is more likely than not to be recovered based on current or future taxable profit.

Deferred tax liabilities are presented within provisions for liabilities on the balance sheet.

Tangible assets

Tangible assets are stated at cost, less accumulated depreciation and accumulated impairment losses. The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation of tangible assets

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class

Depreciation method and rate

Improvements to property

20% straight line basis

Plant and machinery

33%, 20% and10% straight line basis

Business combinations

Business combinations are accounted for using the purchase method. The consideration for each acquisition is measured at the aggregate of the fair values at acquisition date of assets given, liabilities incurred or assumed, and equity instruments issued by the group in exchange for control of the acquired, plus any costs directly attributable to the business combination. When a business combination agreement provides for an adjustment to the cost of the combination contingent on future events, the group includes the estimated amount of that adjustment in the cost of the combination at the acquisition date if the adjustment is probable and can be measured reliably.

 

Cytoplan Limited

Notes to the Financial Statements
for the Year Ended 31 August 2020

Intangible assets

Intangible fixed assets are measured at cost less accumulative amortisation and any accumulative amortisation losses.

Amortisation

Amortisation is provided on intangible assets so as to write off the cost, less any estimated residual value, over their useful life as follows:

Asset class

Amortisation method and rate

Computer software and consultancy costs

20% & 33.3% straight line basis

Investments

Investments in equity shares which are publicly traded or where the fair value can be measured reliably are initially measured at fair value, with changes in fair value recognised in profit or loss. Investments in equity shares which are not publicly traded and where fair value cannot be measured reliably are measured at cost less impairment.

Interest income on debt securities, where applicable, is recognised in income using the effective interest method. Dividends on equity securities are recognised in income when receivable.

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Stocks

Stocks are measured at the lower of cost and estimated selling prices less costs to complete and sell after making due allowance for obsolete and slow moving items. Cost is determined using the average cost method. The carrying amount of stock sold is recognised as an expense in the period in which the related revenue is recognised. Cost includes direct expenditure and an appropriate proportion of variable overheads.

Creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

 

Cytoplan Limited

Notes to the Financial Statements
for the Year Ended 31 August 2020

Reserves

Called up share capital represents the nominal value of shares that have been issued.

Share premium account includes any premiums received on the issue of share capital. Transaction costs associated with the issuing of shares are deducted from the share premium.

Profit and loss account includes all current and prior period profits and losses.

Revaluation reserve is the surplus or deficit arising on the revaluation of an asset of a company.

Provisions

Provisions are recognised when the company has an obligation at the reporting date as a result of a past event, it is probable that the company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

Leases

Leases in which substantially all the risks and rewards of ownership are retained by the lessor are classified as operating leases. Payments made under operating leases are charged to profit or loss on a straight-line basis over the period of the lease.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

The company operates a defined contribution plan for its employees. A defined contribution plan is a pension plan under which the company pays fixed contributions into a separate entity. Once the contributions have been paid the company has no further payments obligations.

The contributions are recognised as an expense in the profit and loss account when they fall due. Amounts not paid are shown in accruals as a liability in the balance sheet. The assets of the plan are held separately from the company in independently administered funds.

The pension provision is held at revaluation and will be subject to revaluation every five years.

3

Staff numbers

The average number of persons employed by the company (including directors) during the year was 51 (2019 - 51).

 

Cytoplan Limited

Notes to the Financial Statements
for the Year Ended 31 August 2020

4

Intangible assets

Computer software and consultancy
 £

Total
£

Cost or valuation

At 1 September 2019

166,204

166,204

Additions acquired separately

169,589

169,589

At 31 August 2020

335,793

335,793

Amortisation

At 1 September 2019

73,399

73,399

Amortisation charge

41,199

41,199

At 31 August 2020

114,598

114,598

Carrying amount

At 31 August 2020

221,195

221,195

At 31 August 2019

92,805

92,805

 

Cytoplan Limited

Notes to the Financial Statements
for the Year Ended 31 August 2020

5

Tangible assets

Land and buildings
£

Plant and machinery
 £

Total
£

Cost or valuation

At 1 September 2019

240,254

266,288

506,542

Additions

420

50,613

51,033

Disposals

-

(4,803)

(4,803)

At 31 August 2020

240,674

312,098

552,772

Depreciation

At 1 September 2019

142,435

110,383

252,818

Charge for the year

19,621

32,023

51,644

At 31 August 2020

162,056

142,406

304,462

Carrying amount

At 31 August 2020

78,618

169,692

248,310

At 31 August 2019

97,819

155,905

253,724

Included within the net book value of land and buildings above is £78,618 (2019 - £97,819) in respect of leasehold land and buildings.
 

6

Investments

2020
£

2019
£

Investments in subsidiaries

200

200

Subsidiaries

£

Cost or valuation

At 1 September 2019 and 31 August 2020

200

Carrying amount

At 31 August 2020

200

At 31 August 2019

200

 

Cytoplan Limited

Notes to the Financial Statements
for the Year Ended 31 August 2020

Details of undertakings

Details of the investments (including principal place of business of unincorporated entities) in which the company holds 20% or more of the nominal value of any class of share capital are as follows:

Undertaking

Registered office

Holding

Proportion of voting rights and shares held

     

2020

2019

Subsidiary undertakings

Nature's Own Limited

Unit 8
Hanley Workshops
Hanley Road
Hanley Swan
Worcester
WR8 0DX

Ordinary shares

100%

100%

 

England

     

Biogrow Limited

Unit 8
Hanley Workshops
Hanley Road
Hanley Swan
Worcester
WR8 0DX

Ordinary shares

100%

100%

 

England

     

Subsidiary undertakings

Nature's Own Limited

The principal activity of Nature's Own Limited is that of a dormant company.

Biogrow Limited

The principal activity of Biogrow Limited is the growing of non-perennial crops.

 

Cytoplan Limited

Notes to the Financial Statements
for the Year Ended 31 August 2020

7

Other financial assets (current and non-current)

Financial assets at cost less impairment
£

Total
£

Current financial assets

Cost or valuation

Additions

250,000

250,000

At 31 August 2020

250,000

250,000

Carrying amount

At 31 August 2020

250,000

250,000

8

Stocks

2020
£

2019
£

Finished goods and goods for resale

1,554,327

1,512,497

 

Cytoplan Limited

Notes to the Financial Statements
for the Year Ended 31 August 2020

9

Debtors

2020
 £

2019
 £

Trade debtors

124,412

197,252

Other debtors

85,987

173,878

Total current trade and other debtors

210,399

371,130

10

Creditors

Creditors: amounts falling due within one year

Note

2020
£

2019
£

Due within one year

 

Trade creditors

 

372,184

337,584

Amounts owed to group undertakings and undertakings in which the company has a participating interest

200

200

Taxation and social security

 

175,771

162,188

Corporation tax

 

209,738

110,473

Other creditors

 

157,511

174,417

 

915,404

784,862

Due after one year

 

Other non-current financial liabilities

 

14,200

15,250

Amounts owed to group undertakings and undertakings in which the company has a participating interest, are interest free and repayable on demand.

 

Cytoplan Limited

Notes to the Financial Statements
for the Year Ended 31 August 2020

11

Financial commitments, guarantees and contingencies

Amounts not provided for in the balance sheet

The total amount of financial commitments not included in the balance sheet is £548,449 (2019 - £531,071).

The total amount of contingencies not included in the balance sheet is £44,000 (2019 - £12,000). There is an unlimited cross-company guarantee dated 10 October 1997 in respect of group liabilities to HSBC. The company has indemnified its bankers against any loss sustained under a bank guarantee in respect of HM Customs and Excise of £20,000 given on the company's behalf on 1 September 2019.

A further guarantee with specific regard to a bank overdraft facility of £24,000 was given to HSBC on 06 June 2020. The overdraft is repayable on demand and is secured upon the assets of the company.

12

Parent and ultimate parent undertaking

The company is controlled by the AIM Foundation, a charity registered in the UK set up by Ian Marks, former Director of Cytoplan Limited by virtue of its 100% beneficial holding in the company's issued ordinary share capital. The parent undertaking of the largest and smallest group preparing group accounts is the AIM Foundation.

 The company's immediate parent is AIM Foundation .

  These financial statements are available upon request from the Charity Commission.

 

13

Audit Report

The Independent Auditor's Report was unqualified. The name of the Senior Statutory Auditor who signed the audit report on 6 May 2021 was Stephanie Henshaw, who signed for and on behalf of PKF Francis Clark.

14

Provisions for liabilities

£

£

Pension provision

1,309,721

1,309,721

Deferred tax liabilities

73,036

58,951

1,382,757

1,368,672